Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.41 |
| ▸ | TP53 | P04637 | 6/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | HPGD | P15428 | 4/20 | 0.41 |
| ▸ | USP2 | O75604 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 7/20 | 0.40 |
| ▸ | CLK4 | Q9HAZ1 | 4/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | CASP7 | P55210 | 2/20 | 0.40 |
| ▸ | APEX1 | P27695 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5462036 | 0.89 | KMT2A (0.48) | MAPTTP53CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL941232 | 0.88 | SMN1; SMN2 (0.42) | MAPTTP53CYP3A4CYP2C19HPGD | |
| SCHEMBL940755 | 0.88 | KMT2A (0.40) | MAPTTP53CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL940803 | 0.86 | ADORA2A (0.41) | MAPTTP53CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL940178 | 0.86 | ALDH1A1 (0.41) | MAPTTP53HSD17B10KMT2AHPGD | |
| SCHEMBL939938 | 0.81 | KMT2A (0.37) | MAPTTP53CYP3A4CYP2C19KMT2A | |
| SCHEMBL942101 | 0.81 | KMT2A (0.39) | MAPTTP53CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL5231317 | 0.80 | ABCG2 (0.38) | MAPTTP53KMT2AMEN1TSHR | |
| SCHEMBL940681 | 0.79 | PKM (0.39) | MAPTTP53CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL940613 | 0.77 | CYP1A2 (0.41) | MAPTTP53CYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8071601-B2 | Aminoquinoline derivatives and their use as adenosine A3 ligands | SANOFI-AVENTIS (FR) | 2011-12-06 | — | — | US | disclosed |
| US-20110112092-A1 | AMINOQUINOLINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS | SANOFI-AVENTIS (FR) | 2011-05-12 | — | — | US | disclosed |
| US-20110009626-A1 | AMINOQUINOLINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS | SANOFI-AVENTIS (FR) | 2011-01-13 | — | — | US | disclosed |
| US-7799922-B2 | Aminoquinoline derivatives and their use as adenosine A3 ligands | SANOFI-AVENTIS (FR) | 2010-09-21 | — | — | US | disclosed |
| US-20090247745-A1 | AMINOQUINOLINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS | SANOFI-AVENTIS (FR) | 2009-10-01 | — | — | US | disclosed |
| US-7547696-B2 | Such as 4-methoxy-N-[6-(morpholin-4-yl)-4-benzylamino-3-cyanoquinolin-2-yl]-benzamide; improved solubility | SANOFI-AVENTIS (FR) | 2009-06-16 | — | — | US | disclosed |
| EP-1663982-B1 | AMINOQUINOLINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS | SANOFI AVENTIS (FR) | 2007-11-21 | — | — | EP | disclosed |
| US-20060211689-A1 | Aminoquinoline derivatives and their use as adenosine A3 ligands | SANOFI-AVENTIS U.S. LLC (US) | 2006-09-21 | — | — | US | disclosed |
| EP-1663982-A1 | AMINOQUINOLINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS | Sanofi-Aventis (FR) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005009969-A1 | AMINOQUINOLINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS | SANOFI-AVENTIS (FR) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211689-A1 | Aminoquinoline derivatives and their use as adenosine A3 ligands | ADORA3, ADORA2A, ADORA1 | MAPT 1043/4885TP53 3233/4885CYP1A2 1001/4885 |
| US-20090247745-A1 | AMINOQUINOLINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS | ADORA3, ADORA2A, ADORA1 | MAPT 1043/4885TP53 3233/4885CYP1A2 1001/4885 |
| US-20110112092-A1 | AMINOQUINOLINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS | ADORA3, ADORA2A, ADORA2B | MAPT 4773/4885TP53 2824/4885CYP1A2 593/4885 |
| US-20110009626-A1 | AMINOQUINOLINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS | ADORA3, ADORA2A, ADORA2B | MAPT 4709/4885TP53 2336/4885CYP1A2 508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.